Summary

Tokyo Gas Co., Ltd. - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Tokyo Gas Co., Ltd. (Tokyo Gas or 'the company') is a provider of LPG and engaged in the production, generation, and transportation of natural gas. The company is also involved in the production, supply and sale of electricity and providing engineering solutions and gas installation work. Its business activities include, gas pipeline services, engineering services, construction, leasing and management of land and buildings. The company offers products and services to residential, commercial, public, medical and industrial sectors and to other gas companies. It provides gas services to Tokyo, Ibaraki, Tochigi, Kanagawa, Saitama, Chiba, and Gunma. Tokyo Gas primarily operates in the Kanto region in Japan. The company is headquartered in Tokyo, Ja...

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated...

Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The G8 countries contributed $1,61,715.9 million in 2023 to the global generics industry, with a compound annual growth rate (CAGR) of 5.8% between 2019 and 2023. The G8 countries are expected to reach a value of $2,15,698.2 million in 2028, with a CAGR of 5.9% over the 2023-28 period.
- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $74,229.0 million in 2023. This was followed by Germany and the UK, with a value of $27,662.3 and $15,516.9 million, respectively.
- The US is expected to lead the generics industry in the G8 nations with a value of $98,531.3 million in 2016, followed by Germany and the UK with expected values of $33,345.6 and $23,397.0 million,...

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated...

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $1,68,484.5 million in 2023. Russia was the fastest growing country with a CAGR of 16.2% over the 2019-23 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of $1,21,016.7 million in 2023. This was followed by India, Russia and Brazil with a value of $22,824.0, $15,429.5, and $9,214.4 million, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of $1,77,196.9 million in 2028, followed by India, Russia, Brazil with expected values of $31,455.5, $19,230....

Summary

The Emerging 5 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- These countries contributed $1,61,156.7 million to the global generics industry in 2023, with a compound annual growth rate (CAGR) of 12.1% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $2,33,053.5 million in 2028, with a CAGR of 7.7% over the 2023-28 period.
- Within the generics industry, China is the leading country among the top 5 emerging nations, with market revenues of $1,21,016.7 million in 2023. This was followed by India and Brazil with a value of $22,824.0 and $9,214.4 million, respectively.
- China is expected to lead the generics industry in the top five emerging nations, with a value of $1,77,196.9 million in 2028, followed by India and Brazil with exp...

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $88,125.3 million in 2023.The Canada was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $74,229.0 million in 2023. This was followed by Canada and Mexico, with a value of $7,717.8 and $6,178.6 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $98,531.3 million in 2028, followed by Canada and Mexico with expected...

Summary

The BRIC Confectionery industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the confectionery industry and had a total market value of $38,658.9 million in 2021. India was the fastest growing country with a CAGR of 8.1% over the 2017-21 period.
- Within the confectionery industry, China is the leading country among the BRIC nations with market revenues of $19,555.4 million in 2021. This was followed by Russia, Brazil and India with a value of $8,828.7, $5,938.0, and $4,336.8 million, respectively.
- China is expected to lead the confectionery industry in the BRIC nations with a value of $22,502.3 million in 2026, followed by Russia, Brazil, India with expecte...

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to the leading competitors.

The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: Organization and Management, Acquisitions and Divestitures, Facilities and Employees, Research and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Directions. ...

Summary

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Australian generics market had total revenues of $1.2bn in 2018, representing a compound annual growth rate (CAGR) of 1.6% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 5.5% between 2014 and 2018, to reach 59.8% of total pharma volume.
- The subsidized cost o...

Summary

Generics in Russia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Russian generics market had total revenues of $8.5bn in 2018, representing a compound annual growth rate (CAGR) of 12.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 6.2% between 2014 and 2018, to reach 67.6% of total pharma volume.
- Both generics and patented...

Summary

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The French generics market had total revenues of $4.2bn in 2018, representing a compound annual growth rate (CAGR) of 1.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 1.4% between 2014 and 2018, to reach 81% of total pharma volume 2018.
- The French market has bee...

Summary

Generics in Germany industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The German generics market had total revenues of $23.0bn in 2018, representing a compound annual growth rate (CAGR) of 4.9% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 0.8% between 2014 and 2018, to reach 87.5% of total pharma volume.
- Germany has one of the hig...

Summary

Generics in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Italian generics market had total revenues of $1.4bn in 2018, representing a compound annual growth rate (CAGR) of 4.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 3.9% between 2014 and 2018, to reach 22.2% of total pharma volume.
- Italy has one of the lowest ...

Summary

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Dutch generics market had total revenues of $1.1bn in 2018, representing a compound annual growth rate (CAGR) of 2.1% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2% between 2014 and 2018, to reach 77.2% of total pharma volume.
- The Dutch government i...

Summary

Generics in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Spanish generics market had total revenues of $3.8bn in 2018, representing a compound annual growth rate (CAGR) of 2.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 0.6% between 2014 and 2018, to reach 40% of total pharma volume.
- The share of the pharmaceutica...

Summary

Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The UK generics market had total revenues of $12.8bn in 2018, representing a compound annual growth rate (CAGR) of 12.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 0.3% between 2014 and 2018, to reach 85% of total pharma volume.
- As the government ha...

Summary

Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Turkish generics market had total revenues of $2.0bn in 2018, representing a compound annual growth rate (CAGR) of 21.2% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 1.6% between 2014 and 2018, to reach 59.4% of total pharma volume.
- Despite being launched in ...

Summary

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The global generics market had total revenues of $328.4bn in 2018, representing a compound annual growth rate (CAGR) of 7.1% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2.3% between 2014 and 2018, to reach 61.8% of total pharma volume in 2018.
- Growth is expected to...

Summary

Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Asia-Pacific generics market had total revenues of $125.7bn in 2018, representing a compound annual growth rate (CAGR) of 8.8% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2.4% between 2014 and 2018, to reach 60.9% of the total pharma volume.
- China aims...

Summary

Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The European generics market had total revenues of $73.0bn in 2018, representing a compound annual growth rate (CAGR) of 6.7% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2.3% between 2014 and 2018, to reach 58.5% of total pharma volume.
- For pharmaceutical compan...

Summary

Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The North American generics market had total revenues of $116.4bn in 2018, representing a compound annual growth rate (CAGR) of 5.6% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 1.3% between 2014 and 2018, to reach 84.1% of total pharma volume.
- The huge si...

Summary

Generics in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Scandinavian generics market had total revenues of $2.7bn in 2018, representing a compound annual growth rate (CAGR) of 4.5% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 3.4% between 2014 and 2018, to reach 41% of total pharma volume.
- The four Scandinavi...

Summary

Generics in China industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Chinese generics market had total revenues of $66.9bn in 2018, representing a compound annual growth rate (CAGR) of 9.2% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 2.5% between 2014 and 2018, to reach 95% of total pharma volume.
- Growth in the Chinese market ...

Summary

Generics in India industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Indian generics market had total revenues of $15.4bn in 2018, representing a compound annual growth rate (CAGR) of 11% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 0.5% between 2014 and 2018, to reach 96.5% of total pharma volume.
- In India, as market saturatio...